Corporate News & Publications

CLINUVEL's company releases, including archives.

Melbourne, Australia, April 12, 2017CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited: Class Number Exercise price CUVAK Conditional Performance Rights subject to various performance milestones, issued various dates under the 2009 and 2014 Plans 25,400 $Nil Consequently, there are now 1,882,260 unlisted conditional performance rights on issue.- End -For more information contact:Darren KeamyCompany SecretaryCLINUVEL PHARMACEUTICALS LIMITEDT: +61 3 9660 4900E: This email address is being protected from spambots. You need JavaScript enabled to view it.-Looking StatementsThis release to the Australian Securities Exchange and to press may contain…
Melbourne, Australia and Leatherhead, UK, US, 12 April 2017 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the treatment of erythropoietic protoporphyria (EPP) patients with CLINUVEL’s drug SCENESSE® (afamelanotide 16mg).CLINUVEL had been in mandatory ‘negotiation’ with GKV-SV since August 2016. Under the German Pharmaceuticals Market Reorganisation Act (AMNOG) a pricing agreement was reached after an Arbitration Board was called. The outcome of the Arbitration Board is legally binding for all state insurers (‘Krankenkassen’) in Germany.aEPP TREATMENT WITH…
Friday, 24 February 2017 19:44

Appendix 4D and Half Year Report

Thursday, 16 February 2017 00:41

CLINUVEL Newsletter - February 2017

Tuesday, 31 January 2017 19:34

Appendix 4C - Quarterly report

Friday, 23 December 2016 20:08

Appendix 3Y

Tuesday, 20 December 2016 22:03

CLINUVEL Newsletter - December 2016

Tuesday, 13 December 2016 02:25

Appendix 3Y

Monday, 28 November 2016 15:01

Results of Meeting

Sunday, 27 November 2016 13:19

Managing Director's AGM Presentation

Page 1 of 53

Quick Links